Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in HPV-negative HNSCC (ADHERE)
NCT03673735Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2021
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 3 trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Jun 2021; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03673735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673735.